Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study
BackgroundBrentuximab vedotin (BV) has demonstrated high remission rates in clinical trials for systemic anaplastic large cell lymphoma (sALCL), yet its real-world effectiveness in China remains unconfirmed. This retrospective observational study evaluates BV-based regimens in patients with sALCL, t...
Saved in:
Main Authors: | Zhiqiang Zhao, Qinchuan Yu, Liping Su, Jianxia He, Jie Tao, Yanfeng Xi, Yujiao Guo, Yanhong Luo, Lieyang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1494384/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SYSTEMATIC REVIEW: ANAPLASTIC LARGE CELL LYMPHOMA FOLLOWING BREAST IMPLANT SURGERY
by: Kezia Eveline, et al.
Published: (2023-06-01) -
Primary Breast Anaplastic Large-Cell Lymphoma
by: Min-Hong Wang, et al.
Published: (2023-10-01) -
Neoadjuvant Immunotherapy and De-escalation of Surgery in Locally Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma
by: Marzia Salgarello, et al.
Published: (2025-01-01) -
TET2-mediated 5-hydroxymethylcytosine of TXNIP promotes cell cycle arrest in systemic anaplastic large cell lymphoma
by: Ziqing Yu, et al.
Published: (2025-01-01) -
An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review
by: Shu-Cheng Wu, et al.
Published: (2024-01-01)